Concomitant administration

Phase 3Biologic

Sanofi

Concomitant administration is one of 55 biologic programs targeting Poliomyelitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PoliomyelitisActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

PoliomyelitisPhase 3

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Taxol

Teva

Phase 3

11 3

Tecentriq

Roche

Phase 3

6 4

Paraplatin

AAvyxa

Phase 3

19 5

Libtayo

Regeneron

Phase 3

5 6

Yervoy

Bristol-Myers Squibb

Phase 3

4 7

Vectibix

Amgen

Phase 3

3 8

Beyfortus

BeiGene

Phase 3

2 9

Gilotrif

Boehringer Ingelheim

Phase 3

10 10

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)

Completed· Sanofi logo

Sanofi·Phase 2·NCT00357149·101 enrolled

Poliomyelitis1 trial

Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old

Completed· Sanofi logo

Sanofi·Phase 3·NCT01249183·954 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Concomitant administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Concomitant administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Concomitant administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Concomitant administration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Poliomyelitis1 trial

References

Drug Info

Quick Facts

Related News